1. Home
  2. SACH vs IXHL Comparison

SACH vs IXHL Comparison

Compare SACH & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.21

Market Cap

52.0M

Sector

Real Estate

ML Signal

HOLD

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$0.41

Market Cap

49.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SACH
IXHL
Founded
2010
2001
Country
United States
Australia
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
52.0M
49.1M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SACH
IXHL
Price
$1.21
$0.41
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
202.8K
24.4M
Earning Date
11-05-2025
11-14-2025
Dividend Yield
16.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,906,000.00
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.08
52 Week High
$1.42
$2.25

Technical Indicators

Market Signals
Indicator
SACH
IXHL
Relative Strength Index (RSI) 69.06 53.22
Support Level $1.00 $0.38
Resistance Level $1.16 $0.50
Average True Range (ATR) 0.05 0.04
MACD 0.02 0.01
Stochastic Oscillator 100.00 54.35

Price Performance

Historical Comparison
SACH
IXHL

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: